Synergy Asset Management LLC Buys 73,084 Shares of Johnson & Johnson (NYSE:JNJ)

Synergy Asset Management LLC lifted its stake in Johnson & Johnson (NYSE:JNJFree Report) by 1,490.6% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 77,987 shares of the company’s stock after acquiring an additional 73,084 shares during the period. Johnson & Johnson accounts for 2.2% of Synergy Asset Management LLC’s portfolio, making the stock its 15th largest position. Synergy Asset Management LLC’s holdings in Johnson & Johnson were worth $12,224,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently added to or reduced their stakes in the business. New Potomac Partners LLC increased its position in Johnson & Johnson by 162.1% during the 4th quarter. New Potomac Partners LLC now owns 3,428 shares of the company’s stock valued at $537,000 after buying an additional 2,120 shares in the last quarter. Next Capital Management LLC acquired a new position in Johnson & Johnson during the 4th quarter valued at about $320,000. ERn Financial LLC increased its position in Johnson & Johnson by 4.6% during the 4th quarter. ERn Financial LLC now owns 6,827 shares of the company’s stock valued at $1,101,000 after buying an additional 303 shares in the last quarter. Patriot Financial Group Insurance Agency LLC increased its position in Johnson & Johnson by 3.1% during the 4th quarter. Patriot Financial Group Insurance Agency LLC now owns 9,416 shares of the company’s stock valued at $1,476,000 after buying an additional 284 shares in the last quarter. Finally, Sharkey Howes & Javer increased its position in Johnson & Johnson by 5.0% during the 4th quarter. Sharkey Howes & Javer now owns 1,879 shares of the company’s stock valued at $295,000 after buying an additional 90 shares in the last quarter. 69.55% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Johnson & Johnson

In other Johnson & Johnson news, major shareholder & Johnson Johnson sold 3,725 shares of the stock in a transaction that occurred on Friday, February 16th. The stock was sold at an average price of $25.81, for a total transaction of $96,142.25. Following the completion of the transaction, the insider now owns 4,099,575 shares of the company’s stock, valued at $105,810,030.75. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In related news, EVP Jennifer L. Taubert sold 59,397 shares of the stock in a transaction that occurred on Friday, February 9th. The stock was sold at an average price of $156.27, for a total value of $9,281,969.19. Following the completion of the sale, the executive vice president now owns 141,416 shares of the company’s stock, valued at $22,099,078.32. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, major shareholder & Johnson Johnson sold 3,725 shares of the stock in a transaction that occurred on Friday, February 16th. The shares were sold at an average price of $25.81, for a total value of $96,142.25. Following the completion of the sale, the insider now directly owns 4,099,575 shares of the company’s stock, valued at approximately $105,810,030.75. The disclosure for this sale can be found here. Insiders own 0.16% of the company’s stock.

Johnson & Johnson Stock Performance

Shares of JNJ stock opened at $157.78 on Tuesday. The company has a market capitalization of $380.22 billion, a P/E ratio of 11.43, a P/E/G ratio of 2.66 and a beta of 0.53. The business’s 50 day moving average is $158.58 and its two-hundred day moving average is $156.57. The company has a current ratio of 1.16, a quick ratio of 0.91 and a debt-to-equity ratio of 0.38. Johnson & Johnson has a 12-month low of $144.95 and a 12-month high of $175.97.

Johnson & Johnson (NYSE:JNJGet Free Report) last issued its quarterly earnings results on Tuesday, January 23rd. The company reported $2.29 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.28 by $0.01. Johnson & Johnson had a return on equity of 37.27% and a net margin of 37.79%. The company had revenue of $21.40 billion for the quarter, compared to the consensus estimate of $21.02 billion. During the same quarter in the prior year, the business posted $2.35 earnings per share. Johnson & Johnson’s revenue for the quarter was down 9.7% on a year-over-year basis. Analysts expect that Johnson & Johnson will post 10.65 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts have recently weighed in on JNJ shares. Morgan Stanley cut their price objective on Johnson & Johnson from $170.00 to $169.00 and set an “equal weight” rating on the stock in a report on Wednesday, January 24th. StockNews.com raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Tuesday, February 6th. Royal Bank of Canada reissued an “outperform” rating and issued a $181.00 price objective on shares of Johnson & Johnson in a report on Wednesday, February 28th. Cantor Fitzgerald reissued an “overweight” rating and issued a $215.00 price objective on shares of Johnson & Johnson in a report on Wednesday, March 13th. Finally, Wells Fargo & Company lowered Johnson & Johnson from an “overweight” rating to an “equal weight” rating and cut their price objective for the company from $170.00 to $163.00 in a report on Wednesday, December 13th. Seven analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $177.31.

Check Out Our Latest Stock Analysis on Johnson & Johnson

About Johnson & Johnson

(Free Report)

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.

Featured Articles

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJFree Report).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.